Core Insights - uniQure N.V. reported updated Phase I/II data for AMT-191 in Fabry disease, showing durable, dose-dependent increases in α-Gal A enzyme activity [1] - The company has a strong financial position with approximately $622.5 million in cash and equivalents as of December 31, 2025, expected to fund operations into the second half of 2029 [1][13] - The CEO expressed confidence in AMT-130 as a potential first disease-modifying therapy for Huntington's disease, despite not yet aligning with the FDA on an approval pathway [2] Financial Performance - Revenue for the year ended December 31, 2025, was $16.1 million, a decrease from $27.1 million in 2024, primarily due to a $10.7 million drop in collaboration revenue [14] - Research and development expenses were $140.7 million for 2025, down from $143.8 million in 2024, mainly due to reduced costs following the divestment of the Lexington facility [16] - The net loss for the year ending December 31, 2025, was $199.0 million, or $3.46 per share, compared to a net loss of $239.6 million, or $4.92 per share, in 2024 [21][22] Clinical Developments - AMT-130 for Huntington's disease showed a statistically significant 75% slowing in disease progression at 36 months compared to an external control [5] - The company completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 for refractory mesial temporal lobe epilepsy, with additional data expected in the first half of 2026 [4][11] - AMT-191 demonstrated dose-dependent elevations in α-Gal A activity, with six of 11 patients withdrawing from enzyme replacement therapy [11] Regulatory Engagement - The company held a Type A meeting with the FDA regarding AMT-130 and plans to request a follow-up Type B meeting in the second quarter of 2026 [4][6] - The FDA indicated that the data from Phase I/II studies compared to an external control may not be sufficient for a marketing application, recommending a prospective, randomized, double-blind study [6] Upcoming Events - uniQure will host an earnings call on March 2, 2026, to discuss its financial results and business updates [1][23] - The company is scheduled to participate in several investor conferences in March and April 2026 [26]

Core Viewpoint - Nykredit Realkredit A/S has received approval to redeem its EUR 500 million Additional Tier 1 Capital Notes, scheduled for redemption on April 15, 2026, at the Outstanding Principal Amount plus accrued interest [1]. Group 1 - Nykredit Realkredit A/S will redeem EUR 500,000,000 Perpetual Non-cumulative Resettable Additional Tier 1 Capital Notes [1]. - The redemption is in accordance with the terms outlined in the Offering Circular [1]. - The redemption date is set for the First Call Date on April 15, 2026 [1].

Core Points - The Annual General Meeting 2026 of A.P. Møller - Mærsk A/S is scheduled for Wednesday, March 25, 2026, at 3:00 p.m. [1] - The meeting will be conducted in English and will be a completely electronic general meeting [1] - Further details, including the agenda and documents, are available on the company's investor relations website [1] - Contact information for the Head of Investor Relations and Head of Media Relations is provided for inquiries [1]

Core Viewpoint - Ocugen, Inc. has completed enrollment for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP), with topline data expected in Q1 2027, which may support a Biologics License Application (BLA) filing and potential approval in 2027 [1][5] Company Developments - The liMeliGhT clinical trial enrolled 140 patients, randomized into treatment and control groups, targeting early- to late-stage RP patients, including pediatric cases [2][3] - The primary endpoint of the trial is the 12-month change in visual function, assessed by a proprietary test called LDNA [2] - Ocugen is on track to file a rolling BLA in Q3 2026, following positive long-term data from a previous Phase 1/2 study showing approximately 2-line gains in visual acuity [4][5] Clinical Trial Insights - The Phase 3 trial is notable for its broad representation of gene mutations associated with RP, supporting a gene-agnostic therapeutic approach [3] - Positive long-term data from the Phase 1/2 study indicated that 88% of evaluable treated subjects showed improvement or preservation of visual function over three years [6] Treatment Landscape - Currently, there are no approved treatments that effectively address the needs of the approximately 98% of RP patients who are not candidates for existing gene therapies [4][9] - OCU400 aims to reset dysfunctional gene networks in retinal cells, potentially improving vision for patients with RP [7][9] Industry Context - RP is a group of rare genetic disorders leading to vision loss, associated with mutations in over 100 genes, highlighting the need for innovative, gene-agnostic therapies [8][9] - The development of novel therapeutic approaches targeting broader RP disease mechanisms offers hope for patients with multiple and unknown genetic mutations [9]

Core Insights - GEEK BAR has officially re-entered the European market with the launch of GEEK BAR SPARK, a new-generation pod system that emphasizes sustainability and regulatory compliance [1][3] Product Development - The GEEK BAR SPARK introduces a reusable pod system designed specifically for Europe, focusing on quality, responsibility, and long-term sustainability [5] - The device features a Starlit Motion Screen that displays real-time battery status through an elegant animation, enhancing usability [6] - Power performance has been upgraded with a high-voltage battery that charges to 80% in just 20 minutes, supporting two full pods per cycle [7] - The SPARK offers a flexible pod ecosystem with both prefilled and refillable options, with the prefilled pod providing up to 1000 puffs and the refillable pod supporting up to 20mL of e-liquid [7] Market Strategy - GEEK BAR aims to deliver a refined taste experience tailored to European preferences, introducing new flavors such as Moonshine Cherries, Tropical Punch, Pineapple Lemon Fizzy, and Apple Cider [9] - The company is enhancing its operational framework with improved supply-chain visibility and a focus on regulatory compliance, aiming for a mature and accountable market entry [11] Brand Positioning - GEEK BAR has established a competitive position in the U.S. market, achieving hundreds of millions of units in cumulative sales and gaining recognition for its flavor delivery and engineering standards [4]

Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains on track to initiate mid-2026 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, March 02, 2026 (GLOBE NEWSWIRE) -- ...

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (TSX.V: AEC; NASDAQ: AEC; FRANKFURT: 0AD) (“Anfield” or the “Company”), announces that the shareholders of the Company considered and voted at the special meeting of shareholders held on February 27, 2026 (the “Special Meeting”) to approve Uranium Energy Corp. (“Uranium Energy”) as a control person of the Company and the issuance by the Company to UEC Energy Corp. (“UEC”), a wholly-owned subsidiary of Uranium Energy, of 896, ...

Intersection includes 55.4 m of 1.96 g/t gold and 9.9 m of 3.22g/t gold Discovery of additional Gold Mineralization expands 826 Zone at Juby Additional Diamond Drill added at site TORONTO, March 02, 2026 (GLOBE NEWSWIRE) -- McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) is pleased to announce further results from its diamond drilling exploration campaign being conducted on its 100%-owned Juby Gold Project, located west of Gowganda, Ontario, within the southern ...

Now in its seventh year, the Loblaw®–Flashfood partnership has delivered more than $295 million in savings while diverting over 105 million pounds of food from landfill nationwide. BRAMPTON, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- Loblaw® and Flashfood mark another successful year of impact, delivering meaningful savings to customers while advancing efforts to reduce food waste across Canada. Through the program, quality food nearing its best-before date ends up on tables instead of going to waste – cre ...

Shareholders are encouraged to vote well in advance of the proxy voting deadline of Friday, March 6, 2026 at 9:00 a.m. (Toronto time).Titanium’s board of directors (with interested directors abstaining from voting) unanimously recommends that Shareholders vote FOR the Arrangement Resolution.Shareholders who have questions or need assistance voting their Common Shares should contact the Company’s proxy solicitation agent, Laurel Hill Advisory Group, by calling or texting “INFO” to 1-877-452-7184 (toll-free i ...